LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Rybelsus (semaglutide) is an oral GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus. Whilst rash is not amongst the most commonly reported adverse effects, the Summary of Product Characteristics acknowledges that hypersensitivity reactions, including rash or urticaria, can occur. Serious allergic reactions such as anaphylaxis and angioedema have been reported with GLP-1 receptor agonists, though these remain uncommon. Any new skin changes warrant proper medical evaluation, as numerous factors beyond medication can cause rashes in people with diabetes. This article examines the evidence regarding Rybelsus and skin reactions, providing guidance on recognition and management.
Quick Answer: Rybelsus can cause rash as part of hypersensitivity reactions, though this is not amongst the most commonly reported side effects.
Rybelsus (semaglutide) is an oral medication licensed in the UK for the treatment of type 2 diabetes mellitus. While rash is not among the most commonly reported side effects of Rybelsus, the Summary of Product Characteristics (SmPC) does note that hypersensitivity reactions can occur, which may include rash or urticaria (hives).
The product information acknowledges that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists like semaglutide, although these are uncommon.
It is important to recognise that any medication can potentially cause skin reactions in susceptible individuals. Patients taking Rybelsus who develop a rash should not automatically assume it is caused by the medication, as skin reactions can arise from numerous causes including concurrent medications, underlying health conditions, allergies to other substances, or unrelated dermatological conditions.
If you develop symptoms of a severe allergic reaction while taking Rybelsus (such as swelling of the face, lips, tongue or throat, breathing difficulties, or widespread rash), you should stop taking the medication and seek immediate medical attention.
This article provides evidence-based information about Rybelsus, its recognised side effects, and guidance on managing skin concerns whilst taking this medication. If you develop a rash or any unexpected skin changes whilst taking Rybelsus, it is important to contact your GP or diabetes specialist nurse for proper evaluation and advice.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
Rybelsus contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking the action of the naturally occurring hormone GLP-1. The medication enhances insulin secretion in a glucose-dependent manner, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. These combined mechanisms help to improve glycaemic control in adults with type 2 diabetes.
The most frequently reported side effects of Rybelsus are gastrointestinal in nature, reflecting the medication's mechanism of action. According to the product literature, these include:
Nausea (very common, affecting more than 1 in 10 people)
Diarrhoea (very common)
Vomiting (common, affecting up to 1 in 10 people)
Abdominal pain (common)
Constipation (common)
Dyspepsia (common)
These gastrointestinal effects are typically most pronounced when initiating treatment or increasing the dose, and often diminish over time as the body adjusts to the medication. According to the SmPC, treatment should start with 3 mg once daily for 30 days, then increase to 7 mg once daily, with a further increase to 14 mg once daily if needed for additional glycaemic control.
Other recognised side effects include hypoglycaemia (particularly when used with insulin or sulfonylureas) and decreased appetite. Diabetic retinopathy complications have been reported, particularly in patients with pre-existing retinopathy, those on insulin, or those experiencing rapid improvement in glucose control. Regular eye monitoring is recommended for these patients.
Acute pancreatitis has been reported in patients using GLP-1 receptor agonists. If pancreatitis is suspected (persistent, severe abdominal pain), Rybelsus should be discontinued immediately and urgent medical assessment sought.
In rodent studies, semaglutide caused thyroid C-cell tumours, though the relevance to humans is unknown. Patients should be counselled about these potential effects before commencing treatment, and healthcare professionals should monitor for any concerning symptoms during follow-up consultations.
Whilst skin reactions are not prominently featured in the adverse effect profile of Rybelsus, the product information does acknowledge that hypersensitivity reactions can occur, which may include cutaneous symptoms such as rash or urticaria (hives).
Injectable formulations of semaglutide (such as Ozempic) have been associated with injection site reactions, but these are not applicable to the oral formulation of Rybelsus. However, patients may experience:
Allergic reactions presenting with urticaria (hives), pruritus (itching), or generalised rash
Non-specific skin changes that may coincide with medication initiation but are not necessarily causally related
Exacerbation of pre-existing skin conditions due to metabolic changes or stress
It is worth noting that patients with diabetes are already at increased risk of various dermatological conditions, including bacterial and fungal infections, diabetic dermopathy, and other skin manifestations related to their underlying condition. Any new skin changes should therefore be evaluated in the context of the patient's overall diabetic control and general health status.
If a rash develops during Rybelsus treatment, healthcare professionals should consider alternative explanations including concurrent medications, dietary changes, new topical products, environmental allergens, or coincidental dermatological conditions. A detailed medication history and examination are essential to establish the most likely cause and determine appropriate management.
If signs of a severe allergic reaction occur (such as swelling of the face, lips, tongue or throat, breathing difficulties, or widespread rash), patients should stop taking Rybelsus immediately and seek urgent medical attention.
Patients taking Rybelsus should be advised to contact their GP or diabetes care team if they develop any new or concerning skin changes. Whilst most rashes are benign and self-limiting, certain features warrant urgent medical assessment:
Seek immediate medical attention (call 999 or attend A&E) if you experience:
Difficulty breathing, wheezing, or throat tightness
Swelling of the face, lips, tongue, or throat (angioedema)
Widespread blistering or skin peeling
Severe rash accompanied by fever, malaise, or joint pain
Signs of anaphylaxis (severe allergic reaction)
Contact your GP promptly (within 24 hours) or call NHS 111 if you develop:
A new rash that is spreading or worsening
Intense itching that affects daily activities or sleep
Rash accompanied by other symptoms such as nausea, vomiting, or abdominal pain
Painful or tender skin lesions
Any rash that does not improve within a few days
When contacting healthcare services, patients should provide relevant information including when the rash started, its location and appearance, any associated symptoms, recent medication changes (including over-the-counter products), and whether they have been exposed to new substances or environments. This information helps clinicians determine whether the rash is likely related to Rybelsus or has an alternative cause.
In general, you should not stop taking Rybelsus without medical advice, as abrupt discontinuation could affect diabetes control. However, if you suspect a severe allergic reaction or acute pancreatitis (persistent, severe abdominal pain), you should stop taking Rybelsus immediately and seek urgent medical assessment. For other situations, your healthcare professional will assess whether the medication needs to be modified and will provide appropriate guidance based on clinical findings.
If you develop a mild rash whilst taking Rybelsus, there are several practical measures that may help whilst awaiting medical assessment:
General skin care measures:
Keep the affected area clean and dry
Avoid scratching, which can worsen irritation and risk infection
Wear loose, breathable cotton clothing to minimise friction
Use fragrance-free, hypoallergenic moisturisers to maintain skin barrier function
Avoid hot baths or showers, which can exacerbate itching
Consider cool compresses for symptomatic relief
Over-the-counter options (after consulting a pharmacist):
Oral antihistamines (such as cetirizine or loratadine) may help with itching
Mild topical corticosteroids (such as hydrocortisone 1% cream) for localised inflammation - use for a maximum of 7 days, avoid applying to the face, genitals, broken or infected skin, and follow age restrictions on the packaging
Emollients to soothe dry or irritated skin
Your healthcare professional will conduct a thorough assessment to determine the cause of the rash and whether it is appropriate to continue Rybelsus. This evaluation may include:
Detailed medication review to identify potential drug interactions or recent additions
Clinical examination to characterise the rash and assess severity
Investigation of alternative causes including infections, allergies, or dermatological conditions
Review of diabetes control, as poor glycaemic management can predispose to skin problems
If the rash is determined to be related to Rybelsus, your doctor may consider dose adjustment, temporary discontinuation, or switching to an alternative diabetes medication. If a true drug allergy to Rybelsus is confirmed, the medication should not be restarted, and this allergy should be documented in your medical records.
In many cases, the rash will have an unrelated cause that can be treated whilst continuing Rybelsus therapy. Regular follow-up ensures that both skin concerns and glycaemic control are appropriately monitored.
If you suspect you have experienced a side effect from Rybelsus, you can report this through the MHRA Yellow Card Scheme (website or app), which helps monitor the safety of medicines in the UK.
Rash is not amongst the most common side effects of Rybelsus, which are predominantly gastrointestinal. However, hypersensitivity reactions including rash or urticaria can occur and are documented in the product information.
Contact your GP or diabetes care team for proper evaluation. If you experience severe allergic symptoms such as facial swelling, breathing difficulties, or widespread rash, stop taking Rybelsus immediately and seek urgent medical attention by calling 999 or attending A&E.
Do not stop Rybelsus without medical advice, as this could affect your diabetes control. Contact your healthcare professional for assessment to determine whether the rash is medication-related and whether it is safe to continue treatment.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
